

EU4H-2021-PJ2: BUILDING THE EU CANCER AND HEALTH GENOMICS PLATFORM

Marc Van Den Bulcke Milano, 4 November 2022

.be

TERMS:

NO CONFLICT OF INTEREST

ALL STATEMENTS ARE ON MY OWN RESPONSABILITY





EUROPEAN COMMISISON AND CANCER












BELGIAN EBCP MIRRORGROUP structure







Cancer Centre participation

EC PROJECTS	Expected outcomes	PROGRAM	PHASE	START DATE			
AG EUCAIM	Cancer Images infrastructure	DIGITAL	Grant Management	1/11/2022			
GDI	Genomics data infrastructure	DIGITAL	Grant Preparation	01/11/2022			
ECIS	Indicators Cancer screening programs	EU4H	Grant Management				
eCAN	Policy on telemonitoring & teleconsultation	EU4H	Grant Preparation	15/09/2022			
CAN.HEAL	Proposals for implementation for new D&T/PHG in cancer	EU4H	Grant Preparation	1/11/2022			
CraNE	Comprehensive Cancer Care Centers and CCC networks	EU4H	Grant Preparation	01/10/2022			
JANE	7 New Networks of Expertise (technical)	EU4H	Grant Preparation	1/10/2022			
PERCH	Vaccination campaings and monitoring	EU4H	Grant Preparation	1/10/2022			
JA Health determinants	Implementation of Best, good practices; pilots; recommendations	EU4H	Proposal preparation	mid 2023			
AG EHDS pilot	Pilots for EHDS	EU4H	Under evaluation	early 2023			
Tender APP Survivorship	digital app	EU4H	Under evaluation	1/11/2022			
Healthy Cloud	Recommendations for use of EHDS	H2020	Grant Management	01/11/2020			
PHIRI	Operation data exchange via EHDS prinicples	H2020	Grant Management	01/11/2020			
oncNGS	Integrated CGP platform	H2020	Grant Management	01/01/2020			
UNCAN.eu	Roadmap research in cancer	HORIZON	Grant Management	01/09/2022			
CSA_CCI4EU	Comprehensive Cancer Infrastructures for research	HORIZON	Under evaluation	2023			
CSA-CanMisHub	National Mirror groups for MoC implementation	HORIZON	Under evaluation	2023			
JA support to JRC Inequalies register	Framework for monitoring EBCP iplementation	EU4H	In preparation	mid 2023			
JA ERNs	under discussion	EU4H	In preparation	mid 2023			
JA Primary use of DATA	under discussion	EU4H	In preparation	mid 2023			
JA CCI	to be opened	EU4H	to be opened	2024			





EBCP-MoC building blocks

Cancer centre involved:

- Comprehensive Cancer Centers (JA CRaNE)
- ► Comprehensive Cancer Care networks (JA CanCON, iPAAC, JA CRaNE)
- ► Comprehensive Cancer Infrastructures (CSA CCI4EU)
- Cancer Mission hubs (CSA unCAN, CSA ECHOS)
- ► ERNs Cancer (ERN initiative, JA ERNs)
- ▶ JRC Inequalities Register (JA Inequalities, App Prvention, App survivorship)
- Networks of Expertise (JANE)
- ► EHDS (AG EHDS pilots, Healthy Cloud, PHIRI, JA TEHDAS,)
- Remote monitoring, consultation and telemedicine (JA eCAN)
- Genomics Dataspace (GDI, 1+MG initiative)
- Cancer Images dataspace (EUCAIM)
- **....**
- Cancer Centre NOT involved:
- Survivorship Digital passport (?)
- Cancer Registers infrastructure (?)
- **...**

ACRONYM	Expected outcomes							
AG EUCAIM	Cancer Images infrastructure							
GDI	Genomics data infrastructure							
CanScreen-ECIS	Indicators Cancer Screening programs							
eCAN	Policy on tele-monitoring & teleconsultation							
CAN.HEAL	Proposals for implementation for new D&T/PHG in cancer							
CraNE	Comprehensive Cancer Care Centers and CCC networks							
JANE	7 New Networks of Expertise (technical, logistic)							
PERCH	HPV Vaccination campaigns and SC/Vac monitoring framework							
JA Health determinants	Implementation of Best/good practices/pilots/recommendations							
AG EHDS pilot	Pilots for EHDS							
Tender APP Prevention	digital app							
Tender APP Survivorship	digital app							
Healthy Cloud	Recommendations for use of EHDS							
PHIRI	Operational data exchange via EHDS principles							
oncNGS	Integrated CGP platform							
UNCAN.eu	Roadmap research in cancer							
CSA_CCI4EU	Comprehensive Cancer Infrastructures for research							
CSA-CanMisHub	National Mirror groups (or equivalent) for MoC implementation							

Building the EU Cancer and Health Genomics platform

CAN. HEAL

CALL: EU4H-2021-PJ-15: Cancer Diagnostic and Treatment for All - Genomic for Public Health

OBJECTIVES OF THE CALL:

The new 'Cancer Diagnostic and Treatment for All' initiative, and the 'Genomic for Public Health' project will help Member States to

improve access for individuals and cancer patients and survivors to prevention, diagnosis and treatment of cancer through personalised medicine, by upscaling available innovation in the field of innovative cancer diagnosis and treatment.

Sub-topic (a) 'Cancer Diagnostic and Treatment for All' initiative

It will use the 'next generation sequencing' technology for a quick and efficient application of personalised cancer diagnosis and treatment.

The action will scale up the already available results in genetic profiling of patients and tumour cells allowing cancer centres to share such cancer profiles with a view to apply the same or similar diagnostic and therapeutic approaches to patients with comparable cancer profiles across the Union.

<u>Sub-topic (b) - 'Genomic for Public Health' project:</u>

which is expected, to scale up the '1+ Million Genome Initiative' results, to translate them into implementable public health measures to address cancer prevention on the basis of specific individual genetic profiles, which indicates the susceptibility of individuals to develop a certain type of cancer.

Therefore, the project will open **new perspectives to personalised risk-assessment and targeted cancer prevention**.

EXPECTED RESULTS AND IMPACT:

Actions will help Member States to develop guidelines and recommendations to better determine who and what to test, organise health services to implement genetic testing, and provide specific education and training for health workers to advance our understanding of cancer control. Ultimately, individuals and cancer patients will benefit on a large-scale of a high quality and viable way to prevent cancer, to diagnose and treat it.

43 Participating organizations in 16 countries:


Belgium	Ghent University
g	Jessa Hospital
	Jules Bordet Institute
	Katholieke Universiteit Leuven
	Sciensano
	University of Liège
	Digital Institute for Cancer Outcomes Research EEIG
Czech Republik	Institute of hematology and blood transfusion
Denmark	Aarhus University
Estonia	University of Tartu
France	Hospices Civils de Lyon
	INSERM
	Institut Curie
Germany	Charité - University Medical Center Berlin
	Hannover Medical School
	University of Tübingen
	University Medical Center Hamburg- Eppendorf/The European Liquid Biopsy Society Consortium
	Medical Center, University of Schleswig- Holstein, Lübeck
Greece	Institute of Applied BioSciences
	Hellenic Cancer Federation - ELLOK
International organisations	European Alliance for personalized Medicine (EAPM)
	European Cancer Patient Coalition (ECPC)

Instituto Superiore di Sanita Università Cattolica del Sacro Cuore Latvia Latvian Biomedical Research and Study Centre Luxembourg Malta Ministry for Health Netherlands Erasmus Universitair medisch centrum Rotterdam Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Spain Agencia de qualitat i avaluacio sanitaries de Catalunya		
Università Cattolica del Sacro Cuore Latvia Latvian Biomedical Research and Study Centre Luxembourg Université du Luxembourg Malta Ministry for Health Netherlands Erasmus Universitair medisch centrum Rotterdam Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Italy	Alleanza contro il cancro
Latvia Latvian Biomedical Research and Study Centre Luxembourg Malta Ministry for Health Netherlands Erasmus Universitair medisch centrum Rotterdam Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya		Instituto Superiore di Sanita
Luxembourg Malta Ministry for Health Netherlands Erasmus Universitair medisch centrum Rotterdam Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Spain Agencia de qualitat i avaluacio sanitaries de Catalunya		Università Cattolica del Sacro Cuore
Malta Ministry for Health Netherlands Erasmus Universitair medisch centrum Rotterdam Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Latvia	Latvian Biomedical Research and Study Centre
Netherlands Erasmus Universitair medisch centrum Rotterdam Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Luxembourg	Université du Luxembourg
Rijkstinstituut voor Volksgezondheid en Milieu (RIVM) Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Malta	Ministry for Health
Stichting het Nederlands kankerinstituut-Antoni Van Leeuwenhoek ziekenhuis Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Netherlands	Erasmus Universitair medisch centrum Rotterdam
Poland Medical University of Warsaw Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya		Rijkstinstituut voor Volksgezondheid en Milieu (RIVM)
Maria Sklodowska Curie National Research Institute of Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya		
Oncology Portugal Instituto nacional de saude doutor Ricardo Jorge Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Poland	Medical University of Warsaw
Slovenia Institute of Oncology Spain Agencia de qualitat i avaluacio sanitaries de Catalunya		maria dineadifena dario matrenar nescarcir metrate di
Spain Agencia de qualitat i avaluacio sanitaries de Catalunya	Portugal	Instituto nacional de saude doutor Ricardo Jorge
1 rigoriola do quarrent i avaradoro sarritarios do catalarija	Slovenia	Institute of Oncology
Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y Leon	Spain	Fundación Instituto de Estudios de Ciencias de la
Institut Catala d'oncologia		Institut Catala d'oncologia
FISABIO		FISABIO

Summary project


- Build on distinct use cases towards developing an integrated approach to improve access of individuals and cancer patients and survivors to prevention, diagnosis and treatment of cancer through personalised medicine.
- Genomics for Public Health:
 - ▶ Framework for aligning and integrating the genome of Europe biobanking
 - ▶ Polygenic risk score analysis/recommendations for decision support tools and strategies for the implementation of telegenetics and remote genetic counselling
 - ▶ Building clinical utility for cancers in pregnancy, family-based genetic testing in pediatric leukemia, cancer risk stratification
- ► Cancer diagnostics and treatment for all:
 - ▶ Strategies for wet lab tools, comprehensive genomic profiling, data interpretation, data integration, decision support (MTB and tools) for early detection, diagnosis and treatment
- ▶ Implementing NGS-based and liquid biopsy assays in clinical practice
- ▶ Define key legal and ethical requirements for health and medical cancer genomics
- Develop training tools
- Develop recommendations for the implementation of personalized approaches in the healthcare system

Overall structure





- Comprehensive Cancer Centers (JA CRaNE)
- Comprehensive Cancer Care networks (JA CanCON, iPAAC, JA CRaNE)
- Comprehensive Cancer Infrastructures (CSA CCI4EU)
- Cancer Mission hubs (CSA unCAN, CSA ECHOS)
- ERNs Cancer (ERN initiative, JA ERNs)
- ▶ JRC Inequalities Register (JA Inequalities, App Prvention, App survivorship)
- NoE (JANE)
- ► EHDS (AG EHDS pilots, Healthy (RI, JA TEHDAS,)
- Genomics Dataspace (GDI, 1
- Cancer Images dataspace
- **....**
- ► Cancer Centr
- ► Survivorship Dig
- ► Cancer Registers into ructure (?)
- · ...



Can.HEAL Transversal WPs

2024-2030

EUROPE'S BEATING
CANCER PLAN
LET'S STRIVE FOR MORE

#EUCancerPlan
4 February 2020, European Parliament, Brussels

SUSTAINABILITY

EC PROJECTS	Expected outcomes	2022	2023		2024				2025			2026		2	027				\						
AG EUCAIM	Cancer Images infrastructure															-			1				-		
GDI	Genomics data infrastructure										П					-0		92				286	- 97	1	4.0
ECIS	Indicators Cancer screening programs										П					100	9				- 36	100	N.	1	
eCAN	Policy on telemonitoring & teleconsultation										П										100			- 39	
CAN.HEAL	Proposals for implementation for new D&T/PHG in cancer										П									man					200
CraNE	Comprehensive Cancer Care Centers and CCC networks										П									0			100		
JANE	7 New Networks of Expertise (technical)										П								0.0	V (1.75	100	1970	
PERCH	Vaccination campaings and monitoring					П	T				П								72		و ای ر		4		
JA Health determinants	Implementation of Best, good practices; pilots; recommendations				A	JA	ID WP1	LO Pilot	s	Į,			1		7				40	de				7	
AG EHDS pilot	Pilots for EHDS				П															dillo.		AIT	וג רו		
Tender APP Survivorship	digital app																						' 'N		
Healthy Cloud	Recommendations for use of EHDS																		- 1		M.		A		
PHIRI	Operation data exchange via EHDS prinicples				П														- 3		en	9111	16-	• 1	
oncNGS	Integrated CGP platform				П																377	130	16.	100	30.0
UNCAN.eu	Roadmap research in cancer				\vdash														100,000		عاد ال	T. A.			-
CSA CCI4EU	Comprehensive Cancer Infrastructures for research																		-	- B			7 8 B		and a
CSA-CanMisHub	National Mirror groups for MoC implementation																		1	- 4	. #	1	4		
JA support to JRC Inequalies regi	ST Framework for monitoring EBCP iplementation																				, N.	"	*	S	
JA ERNs	under discussion																			-		-	200	-	
JA Primary use of DATA	under discussion																- 1		-						
JA CCI	to be opened																								

CANCER CENTER - SCIENSANO

Marc Van Den Bulcke Els Van Valckenborgh Aline Hébrant Gordana Raicevic Pauline Wurstemberger Barthélémy Emilie Cauët Hélène Antoine-Poirel Marie Delnord Souhade Tabakkalt

HEALTHDATA.BE - SCIENSANO

Johan Van Bussel

OUALITY OF LABORATORIES - SCIENSANO

Aline Antoniou Nicolas Loucheu

COMPERMED

>200 experts

NIHDI (RIZIV/INAMI)

Walli Van dooren Koen Desmedt Evelyn Van Gestel

MINISTRY OF HEALTH (FOD-VVVL)

Saskia Van den Bogaert

BELGIAN CANCER REGISTRY

Nancy Van damme

oncNGS PARTNERS (Buyers)

SC, IJB, ICO, IC, HCU, ACC, CH, LMU

EBCP & 1+Million Genomes Mirrorgoups

>250 experts



Contact

Marc Van den Bulcke Head of Service Cancer Centre Epidemiology and public health T + 32 2 642 5760 Email: marcvandenbulcke@sciensano.be

